Literature DB >> 20729108

Clinical and genetic characteristics of Korean patients with Gaucher disease.

Seon-Yong Jeong1, Sang-Jin Park, Hyon J Kim.   

Abstract

Gaucher disease (GD) is an autosomal recessive glycolipid lysosomal storage disease caused by a deficiency of the β-glucocerebrosidase enzyme (GBA). Allelic heterogeneity in GD has been well described. To date, more than 270 different GBA mutations have been reported. In order to determine the GBA mutation spectrum in Korean GD patients, we performed GBA mutation analysis of Korean patients and identified 72 GBA mutant alleles from 36 unrelated patients (100% identification), including 60 single-nucleotide substitutions, 6 single-nucleotide deletions, 4 recombinants, 1 splicing error, and 1 complex allele. N370S, the most common GBA mutation, was not detected, and most of the Korean GBA mutations were previously known to be rare, with the exception of L444P (~21%). Three mutations, P201H, F347L+L444P, and c.630delC, are novel. Examination of the GBA mutant alleles found in 6 ethnic groups revealed that the prevalences of GBA mutant alleles in Korean patients are very different from those seen in Jewish, non-Jewish Caucasian, and Italian patients, but similar to those seen in Japanese and Chinese patients. Our data may provide greater understanding of GBA allelic heterogeneity and an Asian perspective(1) on correlations between genotypes and phenotypes, which may help further the development of better management strategies for patients with GD.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20729108     DOI: 10.1016/j.bcmd.2010.07.010

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  19 in total

Review 1.  Revised recommendations for the management of Gaucher disease in children.

Authors:  Paige Kaplan; Hagit Baris; Linda De Meirleir; Maja Di Rocco; Amal El-Beshlawy; Martina Huemer; Ana Maria Martins; Ioana Nascu; Marianne Rohrbach; Lynne Steinbach; Ian J Cohen
Journal:  Eur J Pediatr       Date:  2012-07-08       Impact factor: 3.183

2.  Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning.

Authors:  Raquel Romero; Arvind Ramanathan; Tony Yuen; Debsindhu Bhowmik; Mehr Mathew; Lubna Bashir Munshi; Seher Javaid; Madison Bloch; Daria Lizneva; Alina Rahimova; Ayesha Khan; Charit Taneja; Se-Min Kim; Li Sun; Maria I New; Shozeb Haider; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-26       Impact factor: 11.205

Review 3.  Gaucher disease.

Authors:  Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

4.  Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease.

Authors:  Yanyan Peng; Benjamin Liou; Venette Inskeep; Rachel Blackwood; Christopher N Mayhew; Gregory A Grabowski; Ying Sun
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

5.  Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia.

Authors:  Eun Ah Kim; Young Tae Lim; Jeong Ok Hah; Young Bae Sohn; Yu Kyung Kim; Joon Hyuk Choi; Sae Yoon Kim; Kyung Mi Jang; JiYoung Ahn; Jae Min Lee
Journal:  Int J Hematol       Date:  2018-11-19       Impact factor: 2.490

6.  Pharmacotherapy of Gaucher Disease: Current and Future Options.

Authors:  Lunawati L Bennett; Chris Fellner
Journal:  P T       Date:  2018-05

7.  Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups.

Authors:  Ju-Young Lee; Beom Hee Lee; Gu-Hwan Kim; Chang-Woo Jung; Jin Lee; Jin-Ho Choi; Han-Wook Yoo
Journal:  Korean J Pediatr       Date:  2012-02-14

8.  Current and emerging pharmacotherapy for Gaucher disease in pediatric populations.

Authors:  Richard Sam; Emory Ryan; Emily Daykin; Ellen Sidransky
Journal:  Expert Opin Pharmacother       Date:  2021-03-25       Impact factor: 4.103

9.  Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.

Authors:  Sonya Barnes; You-Hai Xu; Wujuan Zhang; Benjamin Liou; Kenneth D R Setchell; Liming Bao; Gregory A Grabowski; Ying Sun
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

Review 10.  Imiglucerase in the treatment of Gaucher disease: a history and perspective.

Authors:  Patrick B Deegan; Timothy M Cox
Journal:  Drug Des Devel Ther       Date:  2012-04-18       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.